Morgan Adam Insider Trades

Insider Trading History

Track insider trading activity for Morgan Adam. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Heron Therapeutics
Heron Therapeutics HRTX
Director
Holding Value $55.3k 123,737 shares
Last Trade
Jan 30, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$71.2k 53,960 shares
$1.32
$0.45
Heron Therapeutics
Heron Therapeutics HRTX
Director
Holding Value $3.91M 8,753,290 shares
Last Trade
Aug 08, 2025 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$2.42M 1,836,558 shares
$1.32
$0.45
Heron Therapeutics
Heron Therapeutics HRTX
Director
Holding Value $31.2k 69,777 shares
Last Trade
Jan 31, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$61k 35,900 shares
$1.70
$0.45
Heron Therapeutics
Heron Therapeutics HRTX
Director
Holding Value $31.2k 69,777 shares
Last Trade
Jan 30, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$62.1k 35,900 shares
$1.73
$0.45
Alimera Sciences
Alimera Sciences ALIM
10% owner
Holding Value $0 0 shares
Last Trade
Sep 16, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$27.9M 5,030,550 shares
$5.54
$5.54
Heron Therapeutics
Heron Therapeutics HRTX
Director
Holding Value $37.4k 83,685 shares
Last Trade
Jan 19, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$175k 83,685 shares
$2.09
$0.45
Alimera Sciences
Alimera Sciences ALIM
10% owner
Holding Value $277k 50,000 shares
Last Trade
Oct 02, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$150k 50,000 shares
$2.99
$5.54
Alimera Sciences
Alimera Sciences ALIM
10% owner
Holding Value $52.2M 9,429,808 shares
Last Trade
Aug 15, 2023 Purchase (Conversion)Shares acquired or disposed through conversion of a derivative or other security.
$42.7M 11,948,879 shares
$3.57
$5.54
Alimera Sciences
Alimera Sciences ALIM
10% owner
Holding Value $0 0 shares
Last Trade
Aug 15, 2023 Sale (Conversion)Shares acquired or disposed through conversion of a derivative or other security.
$46.4k 13,000 shares
$3.57
$5.54
Heron Therapeutics
Heron Therapeutics HRTX
Director
Holding Value $3.12M 6,986,744 shares
Last Trade
Jul 21, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$3.41M 2,486,744 shares
$1.37
$0.45
Alimera Sciences
Alimera Sciences ALIM
10% owner
Holding Value $4.43M 800,000 shares
Last Trade
May 17, 2023 Sale (Other)Another type of insider transaction reported on SEC Form 4.
$4.32M 2,057,143 shares
$2.10
$5.54
Alimera Sciences
Alimera Sciences ALIM
10% owner
Holding Value $9.19M 1,659,654 shares
Last Trade
May 17, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$2.92M 1,417,018 shares
$2.06
$5.54
Alimera Sciences
Alimera Sciences ALIM
Director
Holding Value $10.1k 1,825 shares
Last Trade
Mar 26, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.47k 1,825 shares
$1.35
$5.54
Alimera Sciences
Alimera Sciences ALIM
Director
Holding Value $1.43M 257,753 shares
Last Trade
Mar 24, 2023 Sale
$3.86M 2,857,143 shares
$1.35
$5.54
Heron Therapeutics
Heron Therapeutics HRTX
Director
Holding Value $102k 227,272 shares
Last Trade
Feb 22, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$614k 227,272 shares
$2.70
$0.45

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up